A Phase 2 Study of Lenvatinib in Patients With RET Fusion-Positive Lung Adenocarcinoma

Lung cancer is responsible for an estimated 1.7 million deaths worldwide per year, and additional therapeutic options represents an area of unmet need [1,2]. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases with adenocarcinoma representing 36% to 60% of cases [3 –5].

Source: Lung Cancer - September 15, 2019 Category: Cancer & Oncology Authors: Toyoaki Hida, Vamsidhar Velcheti, Karen L. Reckamp, Hiroshi Nokihara, Pallavi Sachdev, Tomoki Kubota, Takuya Nakada, Corina E. Dutcus, Min Ren, Tomohide Tamura Source Type: research